Oral contraceptives and the risk of death from breast cancer

Obstetrics and Gynecology

Volumn 110, Issue 4, 2007, Pages 793-800

  Wingo, Phyllis A ^b   Austin, Harland ^b   Marchbanks, Polly A ^b   Whiteman, Maura K ^a   Hsia, Jason ^b   Mandel, Michele G ^b   Peterson, Herbert B ^b   Ory, Howard W ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETYNODIOL DIACETATE; ETYNODIOL DIACETATE PLUS MESTRANOL; MESTRANOL PLUS NORETHISTERONE; MESTRANOL PLUS NORETYNODREL; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEWS AS TOPIC; MIDDLE AGED; RISK ASSESSMENT; TIME FACTORS;

EID: 34848821623     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000284446.22251.6e     Document Type: Article

References (40)

1. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data Vital Health Stat 2004;350:1-36.
2. United States Department of Health and Human Services, National Program of Cancer Registries. Cancer Registry Public Information Data: 1999-2002, WONDER On-line Database. Atlanta (GA): Centers for Disease Control and Prevention; November 2005. Available at http://wonder.cdc.gov/cancer.html. Retrieved April 10, 2006.
3. Sattin RW, Rubin GL, Wingo PA, Webster LA, Ory HW. Oral contraceptive use and the risk of breast cancer. N Engl J Med 1986;315:405-11.
4. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptive use and the risk of breast cancer. N Engl J Med 2002;346:2025-32.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
6. Bernstein L. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 2006;98:288-96.
7. Thomas DB. Oral contraceptives and breast cancer: review of the epidemiologic literature. In: Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee on the Relationship Between Oral Contraceptives and Breast Cancer. Washington, DC: National Academy Press; 1991. p 102-35.
8. Wingo PA, Ory HW, Layde PM, Lee NC. The evaluation of the data collection process for a multicenter, population based, case-control design. Am J Epidemiol 1988;128:206-17.
9. National Cancer Institute, DCCPS, Surveillance Research Program. Surveillance, Epidemiology, and End Results (SEER) Program Public Use Data (1973-1997), Cancer Statistics Branch, released April 2000, based on the August 1999 submission. Available at www.seer.concer.gov. Retrieved July 30, 2007.
10. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Based on the Recommendations of the Ninth Revision, Conference, 1975. Geneva, Switzerland: World Health Organization; 1977.
11. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34:187-220.
12. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Reproductive history and mortality after breast cancer diagnosis. Obstet Gynecol 2004;104:146-54.
13. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2005;14:2009-14.
14. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation of obesity. Geneva, Switzerland: World Health Organization; 1997.
15. Spencer JD, Millis RR, Hayward JL. Contraceptive steroids and breast cancer. Br Med J 1978;1:1024-6.
16. Matthews PN, Millis RR, Hayward JL. Breast cancer in women who have taken contraceptive steroids. Br Med J (Clin Res Ed) 1981;282:774-6.
17. Greenberg ER, Vessey MP, McPherson K, Doll R, Yeates D. Body size and survival in premenopausal breast cancer. Br J Cancer 1985;51:691-7.
18. Rosner D, Lane WW. Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer 1986;57:591-6.
19. Millard FC, Bliss JM, Chilvers CED, Gazet JC. Oral contraceptives and survival in breast cancer. Br J Cancer 1987;56:377-8.
20. Olsson H, Moller TR, Ranstam J, Borg A, Ferno M. Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Res 1988;8:29-32.
21. Lees AW, Jenkins HJ, May CL, Cherian G, Lam EWH, Hanson J. Risk factors and 10-year breast cancer survival in northern Alberta. Breast Cancer Res Treat 1989;13:143-51.
22. Schönborn I, Nischan P, Ebeling K. Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 1994;30:283-92.
23. Holmberg L, Lund E, Bergström R, Adami H-O, Meirik O. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use, and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994;30A:351-4.
24. Schouten LJ, Hupperets PS, Jager JJ, Volovics L, Wils JA, Verbeek AL, et al. Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 1997;43:217-23.
25. Sauerbrei W, Blettner M, Schmoor C, Bojar H, Schumacher M. The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. German Breast Cancer Group. Eur J Cancer 1998;34:1348-51.
26. Reeves GK, Patterson J, Vessey MP, Yeates D, Jones L. Hormonal and other factors in relation to survival among breast cancer patients. Int J Cancer 2000;89:293-9.
27. Seeger H, Rakov V, Mueck AO. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. Horm Metab Res 2005;37:468-73.
28. Isaksson E, von Schoultz E, Odlind V, Soderqvist G, Csemiczky G, Carlstrom K, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-9.
29. Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995;136:164-71.
30. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991;48:206-10.
31. Anderson TJ, Battersby S, King RJB, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20:1139-44.
32. Menendez JA, Oza BP, Colomer R, Lupu R. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol 2005;26:1507-15.
33. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-46.
34. Althius MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
35. Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, et al. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 1999;8:413-9.
36. Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 2003;106:961-4.
37. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva, Switzerland: World Health Organization, 2004 Available at http://www.who.int/ reproductive-health/publications/mec/mec.pdf. Retrieved July 7, 2006.
38. Coulter A, Vessey M, McPherson K, Crossley B. The ability of women to recall their oral contraceptive histories. Contraception 1986;33:127-37.
39. Ries LAG, Harkins D, Krapcho M, editors. Contents of the SEER Cancer Statistics Review, 1975-2003. Bethesda (MD): National Cancer Institute; 2006. Available at http://seer.cancer.gov/csr/1975_2003/. Retrieved July 30, 2007.
40. Rosner B. Fundamentals of biostatistics. 6th ed. Belmont (CA): Duxbury, 2006.